** Morgan Stanley double upgrades investment bank Houlihan Lokey HLI.N to "overweight" from "underweight"
** Says co generally holds up better than peers in risk-off environments and has a lower beta to the overall M&A cycle
** "HLI's skew to the counter-cyclical restructuring business (30% of revenues) and less volatile Financial Advisory & Valuation business (15% of revenues) makes them a more defensive play," brokerage says
** Adds that co sees more opportunity to acquire smaller boutique advisers during downturns, which drives more revenue upside when the cycle turns
** Four of 9 brokerages rate the stock "buy," 4 "hold" and 1 "strong sell"; median PT is $191 — data compiled by LSEG
** HLI stock down nearly 11% YTD, including session moves; it rose around 45% in 2024
(Reporting by Ateev Bhandari in Bengaluru)
((Ateev.Bhandari@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。